Armata Pharmaceuticals (ARMP) Lifted to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) from a sell rating to a hold rating in a research report sent to investors on Friday morning, Zacks.com reports.

According to Zacks, “Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company’s principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. “

Shares of NYSEAMERICAN:ARMP opened at $3.56 on Friday. Armata Pharmaceuticals has a one year low of $2.10 and a one year high of $19.18.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its earnings results on Monday, May 6th. The company reported ($1.54) EPS for the quarter, meeting the consensus estimate of ($1.54).

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains.

Recommended Story: What is a blue-chip stock?

Get a free copy of the Zacks research report on Armata Pharmaceuticals (ARMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.